Highlights of the 2018 Chinese hypertension guidelines
Blood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic hypertension management strategy. The 2018 Chinese hypertension guidelines issued in 2019, after 3 years revision. During the periods, the latest United States (US) and Eur...
Saved in:
| Published in | Clinical hypertension Vol. 26; no. 1; pp. 8 - 6 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
01.05.2020
BioMed Central BMC 대한고혈압학회 |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Blood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic hypertension management strategy. The 2018 Chinese hypertension guidelines issued in 2019, after 3 years revision. During the periods, the latest United States (US) and European guidelines successively published, bringing new thoughts, wisdoms and schemes on hypertension management. This review aims to summarize the highlights of the new Chinese guidelines.
Despite the fact that the 2017 US hypertension guidelines changed hypertension definition from ≥140/90 mmHg to 130/80 mmHg, the Chinese hypertension guidelines did not follow suit, and maintained 140/90 mmHg as the cut-point of for diagnosis of hypertension. A combined, cardiovascular risks and BP levels-based antihypertensive treatment algorithm was introduced. Five classes of antihypertensive drugs, including β-blockers were recommended as initiation and maintenance of BP-lowering therapy. Initiating combination therapy, including single pill combination (SPC) was indicated in high-risk patients or those with grade 2 or 3 hypertension. For those with grade 1 hypertension (BP ≥ 140/90 mmHg), an initial low-dose antihypertensive drugs combination treatment could be considered.
China has never stopped exploring the best strategy for improving hypertension control. Based on clinical evidence and expertise, the newest Chinese guidelines and expert consensus will be of help in guiding physicians and practitioners to provide better management of hypertension in China. |
|---|---|
| AbstractList | Background Blood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic hypertension management strategy. The 2018 Chinese hypertension guidelines issued in 2019, after 3 years revision. During the periods, the latest United States (US) and European guidelines successively published, bringing new thoughts, wisdoms and schemes on hypertension management. This review aims to summarize the highlights of the new Chinese guidelines. Main text Despite the fact that the 2017 US hypertension guidelines changed hypertension definition from [greater than or equai to]140/90 mmHg to 130/80 mmHg, the Chinese hypertension guidelines did not follow suit, and maintained 140/90 mmHg as the cut-point of for diagnosis of hypertension. A combined, cardiovascular risks and BP levels-based antihypertensive treatment algorithm was introduced. Five classes of antihypertensive drugs, including [beta]-blockers were recommended as initiation and maintenance of BP-lowering therapy. Initiating combination therapy, including single pill combination (SPC) was indicated in high-risk patients or those with grade 2 or 3 hypertension. For those with grade 1 hypertension (BP [greater than or equai to] 140/90 mmHg), an initial low-dose antihypertensive drugs combination treatment could be considered. Conclusions China has never stopped exploring the best strategy for improving hypertension control. Based on clinical evidence and expertise, the newest Chinese guidelines and expert consensus will be of help in guiding physicians and practitioners to provide better management of hypertension in China. Keywords: Chinese, Hypertension, Guidelines Blood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic hypertension management strategy. The 2018 Chinese hypertension guidelines issued in 2019, after 3 years revision. During the periods, the latest United States (US) and European guidelines successively published, bringing new thoughts, wisdoms and schemes on hypertension management. This review aims to summarize the highlights of the new Chinese guidelines. Despite the fact that the 2017 US hypertension guidelines changed hypertension definition from ≥140/90 mmHg to 130/80 mmHg, the Chinese hypertension guidelines did not follow suit, and maintained 140/90 mmHg as the cut-point of for diagnosis of hypertension. A combined, cardiovascular risks and BP levels-based antihypertensive treatment algorithm was introduced. Five classes of antihypertensive drugs, including β-blockers were recommended as initiation and maintenance of BP-lowering therapy. Initiating combination therapy, including single pill combination (SPC) was indicated in high-risk patients or those with grade 2 or 3 hypertension. For those with grade 1 hypertension (BP ≥ 140/90 mmHg), an initial low-dose antihypertensive drugs combination treatment could be considered. China has never stopped exploring the best strategy for improving hypertension control. Based on clinical evidence and expertise, the newest Chinese guidelines and expert consensus will be of help in guiding physicians and practitioners to provide better management of hypertension in China. Blood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic hypertension management strategy. The 2018 Chinese hypertension guidelines issued in 2019, after 3 years revision. During the periods, the latest United States (US) and European guidelines successively published, bringing new thoughts, wisdoms and schemes on hypertension management. This review aims to summarize the highlights of the new Chinese guidelines. China has never stopped exploring the best strategy for improving hypertension control. Based on clinical evidence and expertise, the newest Chinese guidelines and expert consensus will be of help in guiding physicians and practitioners to provide better management of hypertension in China. Abstract Background Blood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic hypertension management strategy. The 2018 Chinese hypertension guidelines issued in 2019, after 3 years revision. During the periods, the latest United States (US) and European guidelines successively published, bringing new thoughts, wisdoms and schemes on hypertension management. This review aims to summarize the highlights of the new Chinese guidelines. Main text Despite the fact that the 2017 US hypertension guidelines changed hypertension definition from ≥140/90 mmHg to 130/80 mmHg, the Chinese hypertension guidelines did not follow suit, and maintained 140/90 mmHg as the cut-point of for diagnosis of hypertension. A combined, cardiovascular risks and BP levels-based antihypertensive treatment algorithm was introduced. Five classes of antihypertensive drugs, including β-blockers were recommended as initiation and maintenance of BP-lowering therapy. Initiating combination therapy, including single pill combination (SPC) was indicated in high-risk patients or those with grade 2 or 3 hypertension. For those with grade 1 hypertension (BP ≥ 140/90 mmHg), an initial low-dose antihypertensive drugs combination treatment could be considered. Conclusions China has never stopped exploring the best strategy for improving hypertension control. Based on clinical evidence and expertise, the newest Chinese guidelines and expert consensus will be of help in guiding physicians and practitioners to provide better management of hypertension in China. Background Blood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic hypertension management strategy. The 2018 Chinese hypertension guidelines issued in 2019, after 3 years revision. During the periods, the latest United States (US) and European guidelines successively published, bringing new thoughts, wisdoms and schemes on hypertension management. This review aims to summarize the highlights of the new Chinese guidelines. Main text Despite the fact that the 2017 US hypertension guidelines changed hypertension definition from ≥140/90 mmHg to 130/80 mmHg, the Chinese hypertension guidelines did not follow suit, and maintained 140/90 mmHg as the cut-point of for diagnosis of hypertension. A combined, cardiovascular risks and BP levels-based antihypertensive treatment algorithm was introduced. Five classes of antihypertensive drugs, including β-blockers were recommended as initiation and maintenance of BP-lowering therapy. Initiating combination therapy, including single pill combination (SPC) was indicated in high-risk patients or those with grade 2 or 3 hypertension. For those with grade 1 hypertension (BP ≥ 140/90 mmHg), an initial low-dose antihypertensive drugs combination treatment could be considered. Conclusions China has never stopped exploring the best strategy for improving hypertension control. Based on clinical evidence and expertise, the newest Chinese guidelines and expert consensus will be of help in guiding physicians and practitioners to provide better management of hypertension in China. Blood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic hypertension management strategy. The 2018 Chinese hypertension guidelines issued in 2019, after 3 years revision. During the periods, the latest United States (US) and European guidelines successively published, bringing new thoughts, wisdoms and schemes on hypertension management. This review aims to summarize the highlights of the new Chinese guidelines.BACKGROUNDBlood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic hypertension management strategy. The 2018 Chinese hypertension guidelines issued in 2019, after 3 years revision. During the periods, the latest United States (US) and European guidelines successively published, bringing new thoughts, wisdoms and schemes on hypertension management. This review aims to summarize the highlights of the new Chinese guidelines.Despite the fact that the 2017 US hypertension guidelines changed hypertension definition from ≥140/90 mmHg to 130/80 mmHg, the Chinese hypertension guidelines did not follow suit, and maintained 140/90 mmHg as the cut-point of for diagnosis of hypertension. A combined, cardiovascular risks and BP levels-based antihypertensive treatment algorithm was introduced. Five classes of antihypertensive drugs, including β-blockers were recommended as initiation and maintenance of BP-lowering therapy. Initiating combination therapy, including single pill combination (SPC) was indicated in high-risk patients or those with grade 2 or 3 hypertension. For those with grade 1 hypertension (BP ≥ 140/90 mmHg), an initial low-dose antihypertensive drugs combination treatment could be considered.MAIN TEXTDespite the fact that the 2017 US hypertension guidelines changed hypertension definition from ≥140/90 mmHg to 130/80 mmHg, the Chinese hypertension guidelines did not follow suit, and maintained 140/90 mmHg as the cut-point of for diagnosis of hypertension. A combined, cardiovascular risks and BP levels-based antihypertensive treatment algorithm was introduced. Five classes of antihypertensive drugs, including β-blockers were recommended as initiation and maintenance of BP-lowering therapy. Initiating combination therapy, including single pill combination (SPC) was indicated in high-risk patients or those with grade 2 or 3 hypertension. For those with grade 1 hypertension (BP ≥ 140/90 mmHg), an initial low-dose antihypertensive drugs combination treatment could be considered.China has never stopped exploring the best strategy for improving hypertension control. Based on clinical evidence and expertise, the newest Chinese guidelines and expert consensus will be of help in guiding physicians and practitioners to provide better management of hypertension in China.CONCLUSIONSChina has never stopped exploring the best strategy for improving hypertension control. Based on clinical evidence and expertise, the newest Chinese guidelines and expert consensus will be of help in guiding physicians and practitioners to provide better management of hypertension in China. Background: Blood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic hypertension management strategy. The 2018 Chinese hypertension guidelines issued in 2019, after 3 years revision. During the periods, the latest United States (US) and European guidelines successively published, bringing new thoughts, wisdoms and schemes on hypertension management. This review aims to summarize the highlights of the new Chinese guidelines. Main text: Despite the fact that the 2017 US hypertension guidelines changed hypertension definition from ≥140/90 mmHg to 130/80 mmHg, the Chinese hypertension guidelines did not follow suit, and maintained 140/ 90 mmHg as the cut-point of for diagnosis of hypertension. A combined, cardiovascular risks and BP levels-based antihypertensive treatment algorithm was introduced. Five classes of antihypertensive drugs, including β-blockers were recommended as initiation and maintenance of BP-lowering therapy. Initiating combination therapy, including single pill combination (SPC) was indicated in high-risk patients or those with grade 2 or 3 hypertension. For those with grade 1 hypertension (BP ≥ 140/90 mmHg), an initial low-dose antihypertensive drugs combination treatment could be considered. Conclusions: China has never stopped exploring the best strategy for improving hypertension control. Based on clinical evidence and expertise, the newest Chinese guidelines and expert consensus will be of help in guiding physicians and practitioners to provide better management of hypertension in China. KCI Citation Count: 2 |
| ArticleNumber | 8 |
| Audience | Academic |
| Author | Liu, Jing |
| Author_xml | – sequence: 1 givenname: Jing surname: Liu fullname: Liu, Jing |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32377372$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002606173$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp9kluL1DAYhousuAf3D3ghBUH0omvOhxthGFx3YEGQ9TqkaTrNbCcZk1bYf286XdeZRSSUlOR53y_58p4XJz54WxRvILiCULBPiQAhaAUQqACABFb4RXGGAGUVlUCeHPyfFpcpbUCmKJUSsFfFKUaYc8zRWcFu3Lrr8zekMrTl0NkSASjKZee8TbbsHnY2DtYnF3y5Hl1j-2njdfGy1X2yl4_zRfHj-svd8qa6_fZ1tVzcVoYhMVSCsUaT2kpGtMbGAgsNZxIYjWsNTA1wbWoDoLZNTVsJRINbykVdE9EwTVp8UXycfX1s1b1xKmi3n9dB3Ue1-H63UpIiDDnK7Gpmm6A3ahfdVseHvWC_EOJa6Tg401ulsZDM5EoIUgI1lA3WjNYQcgKkbmj2-jx77cZ6axtj_RB1f2R6vONdl8_0S3EoMWYwG3x4NIjh52jToLYuGdv32tswJoWwlAJzyGVG3z1DN2GMPrdVIQIIFBhg_Jda63wB59uQ65rJVC0Y4gRhQVmmrv5B5dHYrTM5Qa3L60eC9weCzup-6FLoxyG_dzoG3x525KkVf6KUATQDJoaUom2fEAjUFFk1R1blyKp9ZNV0K_FMZNygp-L53K7_n_Q3iQ3q5w |
| CitedBy_id | crossref_primary_10_1007_s00394_020_02423_w crossref_primary_10_1111_jch_14616 crossref_primary_10_1016_j_heares_2024_109067 crossref_primary_10_2147_DDDT_S485851 crossref_primary_10_1186_s12872_021_02049_8 crossref_primary_10_2147_JIR_S424820 crossref_primary_10_1155_2022_6055940 crossref_primary_10_1186_s12886_023_02925_1 crossref_primary_10_2147_IJGM_S499194 crossref_primary_10_1111_imj_16367 crossref_primary_10_1007_s40256_023_00625_1 crossref_primary_10_3389_fpubh_2022_903036 crossref_primary_10_1186_s40885_023_00238_5 crossref_primary_10_1016_j_pmedr_2024_102934 crossref_primary_10_1097_CD9_0000000000000056 crossref_primary_10_1016_j_ultrasmedbio_2023_09_015 crossref_primary_10_12677_acm_2024_143973 crossref_primary_10_1080_07853890_2024_2362880 crossref_primary_10_4081_hls_2024_13034 crossref_primary_10_3389_fendo_2021_689618 crossref_primary_10_1016_j_jad_2023_08_114 crossref_primary_10_1007_s10557_023_07493_6 crossref_primary_10_1186_s13063_022_05999_2 crossref_primary_10_1155_2022_2454678 crossref_primary_10_1038_s41598_025_88000_9 crossref_primary_10_3389_fcvm_2021_762576 crossref_primary_10_1093_humrep_deac201 crossref_primary_10_1186_s12877_022_02972_1 crossref_primary_10_1016_j_ecoenv_2024_117054 crossref_primary_10_1016_j_pmedr_2024_102843 crossref_primary_10_1111_jch_14918 crossref_primary_10_1038_s41538_024_00362_y crossref_primary_10_3389_fcvm_2021_755403 crossref_primary_10_1016_j_eclinm_2024_102626 crossref_primary_10_3389_fcvm_2022_938363 crossref_primary_10_1186_s40885_022_00230_5 crossref_primary_10_1097_MD_0000000000021144 crossref_primary_10_1038_s41440_024_02070_2 crossref_primary_10_3389_fcvm_2023_1177166 crossref_primary_10_1016_j_jare_2025_02_007 crossref_primary_10_1111_jch_14965 crossref_primary_10_1007_s12325_024_02997_5 crossref_primary_10_1016_j_puhe_2024_10_024 crossref_primary_10_1007_s10157_024_02567_7 crossref_primary_10_1186_s12872_021_02390_y crossref_primary_10_1016_j_heliyon_2024_e28523 crossref_primary_10_1186_s12944_023_01920_1 crossref_primary_10_1161_HYPERTENSIONAHA_122_20120 crossref_primary_10_1177_15353702211055838 crossref_primary_10_1186_s12933_023_02068_z crossref_primary_10_1038_s41598_024_76055_z crossref_primary_10_1038_s41598_023_46281_y crossref_primary_10_1093_rheumatology_keaf076 crossref_primary_10_1002_imt2_22 crossref_primary_10_1111_jch_14910 crossref_primary_10_5334_gh_1066 crossref_primary_10_1002_edm2_353 crossref_primary_10_35366_112757 |
| Cites_doi | 10.1056/NEJMoa1511939 10.1161/CIRCULATIONAHA.117.032380 10.1111/ijcp.13426 10.1016/S0140-6736(19)30427-1 10.1093/eurheartj/ehy339 10.1186/s40885-019-0121-0 10.1038/s41440-019-0284-9 10.1186/s40885-019-0124-x 10.1016/S0140-6736(17)32476-5 10.1016/j.jacc.2018.06.056 10.1016/S0140-6736(15)00805-3 10.1186/s40885-019-0123-y 10.1001/jama.2015.2274 10.1161/STROKEAHA.115.009111 10.1111/jch.13609 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020. COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2020 |
| Copyright_xml | – notice: The Author(s) 2020. – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2020 |
| DBID | AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA ACYCR |
| DOI | 10.1186/s40885-020-00141-3 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals Korean Citation Index |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2056-5909 |
| EndPage | 6 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_9523172 oai_doaj_org_article_a3896c57821541a19d3a65b117409ad5 PMC7193361 A627423856 32377372 10_1186_s40885_020_00141_3 |
| Genre | Journal Article Review |
| GeographicLocations | China United States--US |
| GeographicLocations_xml | – name: China – name: United States--US |
| GroupedDBID | 0R~ 5-W 5VS 8JR AAFWJ AAYXX ACGFS ADBBV ADRAZ ADUKV AFPKN AHBYD AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG BAWUL BCNDV BFQNJ BMC C6C CITATION DIK EBS EF. GROUPED_DOAJ HYE IAO IHR IHW ITC KQ8 M48 M~E OK1 PGMZT RBZ ROL RPM RSV SOJ ACRMQ ADINQ AHSBF C24 EJD H13 NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AHMBA ALIPV AZQEC BENPR BPHCQ BVXVI CCPQU DWQXO FYUFA HMCUK K9. MOJWN PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS PROAC UKHRP 7X8 5PM ACYCR |
| ID | FETCH-LOGICAL-c628t-866da4be964aa3ce0e1c7690ca3ba0cb03bcbc01aedb5f908d3f578bb48d6a4f3 |
| IEDL.DBID | DOA |
| ISSN | 2056-5909 1342-2154 2635-6325 |
| IngestDate | Thu Jun 19 03:20:31 EDT 2025 Wed Aug 27 01:04:37 EDT 2025 Thu Aug 21 14:12:42 EDT 2025 Fri Jul 11 07:33:38 EDT 2025 Mon Jun 30 13:21:03 EDT 2025 Wed Mar 19 00:56:58 EDT 2025 Sat Mar 08 18:46:14 EST 2025 Thu May 22 21:20:15 EDT 2025 Thu Jan 02 22:54:23 EST 2025 Thu Apr 24 23:09:08 EDT 2025 Tue Jul 01 01:08:49 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Hypertension Chinese Guidelines |
| Language | English |
| License | The Author(s) 2020. Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c628t-866da4be964aa3ce0e1c7690ca3ba0cb03bcbc01aedb5f908d3f578bb48d6a4f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 https://clinicalhypertension.biomedcentral.com/articles/10.1186/s40885-020-00141-3 |
| OpenAccessLink | https://doaj.org/article/a3896c57821541a19d3a65b117409ad5 |
| PMID | 32377372 |
| PQID | 2404183033 |
| PQPubID | 2040145 |
| PageCount | 6 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9523172 doaj_primary_oai_doaj_org_article_a3896c57821541a19d3a65b117409ad5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7193361 proquest_miscellaneous_2399837179 proquest_journals_2404183033 gale_infotracmisc_A627423856 gale_infotracacademiconefile_A627423856 gale_healthsolutions_A627423856 pubmed_primary_32377372 crossref_primary_10_1186_s40885_020_00141_3 crossref_citationtrail_10_1186_s40885_020_00141_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-05-01 |
| PublicationDateYYYYMMDD | 2020-05-01 |
| PublicationDate_xml | – month: 05 year: 2020 text: 2020-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Clinical hypertension |
| PublicationTitleAlternate | Clin Hypertens |
| PublicationYear | 2020 |
| Publisher | BioMed Central Ltd BioMed Central BMC 대한고혈압학회 |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC – name: 대한고혈압학회 |
| References | M Su (141_CR15) 2017; 390 X Xie (141_CR14) 2016; 387 S Umemura (141_CR10) 2019; 42 M Zhou (141_CR4) 2019; 394 K Kim (141_CR9) 2019; 25 Joint Committee for guideline revision (141_CR1) 2019; 16 L Han (141_CR11) 2015; 46 J Liu (141_CR17) 2019; 73 Z Wang (141_CR5) 2018; 137 Z Wang (141_CR6) 2019; 21 The SPRINT Research Group (141_CR13) 2015; 373 PK Whelton (141_CR2) 2018; 71 Y Qi (141_CR16) 2018; 72 H Kim (141_CR7) 2019; 25 B Williams (141_CR3) 2018; 39 Y Huo (141_CR12) 2015; 313 H Lee (141_CR8) 2019; 25 |
| References_xml | – volume: 373 start-page: 2103 issue: 22 year: 2015 ident: 141_CR13 publication-title: N Engl J Med doi: 10.1056/NEJMoa1511939 – volume: 137 start-page: 2344 issue: 22 year: 2018 ident: 141_CR5 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.117.032380 – volume: 73 start-page: e13426 issue: 12 year: 2019 ident: 141_CR17 publication-title: Int J Clin Pract doi: 10.1111/ijcp.13426 – volume: 394 start-page: 1145 year: 2019 ident: 141_CR4 publication-title: Lancet doi: 10.1016/S0140-6736(19)30427-1 – volume: 71 start-page: e13 year: 2018 ident: 141_CR2 publication-title: Hypertension – volume: 39 start-page: 3021 issue: 33 year: 2018 ident: 141_CR3 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehy339 – volume: 25 start-page: 16 year: 2019 ident: 141_CR7 publication-title: Clin Hypertens doi: 10.1186/s40885-019-0121-0 – volume: 42 start-page: 1235 year: 2019 ident: 141_CR10 publication-title: Hypertens Res doi: 10.1038/s41440-019-0284-9 – volume: 25 start-page: 20 year: 2019 ident: 141_CR8 publication-title: Clin Hypertens doi: 10.1186/s40885-019-0124-x – volume: 16 start-page: 182 issue: 3 year: 2019 ident: 141_CR1 publication-title: J Geriatr Cardiol – volume: 390 start-page: 2559 year: 2017 ident: 141_CR15 publication-title: Lancet doi: 10.1016/S0140-6736(17)32476-5 – volume: 72 start-page: 1201 year: 2018 ident: 141_CR16 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2018.06.056 – volume: 387 start-page: 435 year: 2016 ident: 141_CR14 publication-title: Lancet doi: 10.1016/S0140-6736(15)00805-3 – volume: 25 start-page: 19 year: 2019 ident: 141_CR9 publication-title: Clin Hypertens doi: 10.1186/s40885-019-0123-y – volume: 313 start-page: 1325 issue: 13 year: 2015 ident: 141_CR12 publication-title: JAMA doi: 10.1001/jama.2015.2274 – volume: 46 start-page: 1777 year: 2015 ident: 141_CR11 publication-title: Stroke doi: 10.1161/STROKEAHA.115.009111 – volume: 21 start-page: 1212 issue: 8 year: 2019 ident: 141_CR6 publication-title: J Clin Hypertens doi: 10.1111/jch.13609 |
| SSID | ssj0001559906 ssj0001853425 ssib042018900 |
| Score | 2.3949573 |
| SecondaryResourceType | review_article |
| Snippet | Blood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic hypertension management... Background Blood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic hypertension... Abstract Background Blood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic... Background: Blood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic hypertension... |
| SourceID | nrf doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 8 |
| SubjectTerms | Angiotensin II Antihypertensive agents Blood pressure Cardiology Cardiovascular disease Chinese Clinical medicine Combination drug therapy Committees Diabetes Disease prevention Diuretics Endorsements Enzymes Guidelines Health risk assessment Hypertension Kidney diseases Review Risk factors Stroke 내과학 |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZouXBBVLxSWggIiQOKaseO7ZxQQVQFCU5U2pvlV7ZVq6Qku_-fGSebEoR6Wmk9G2UnM57vc-ZByPtQa9YA8Sgor3UheKyK2itVVA2vIreqERELnH_8lOcX4vuqWk0HbsOUVrnbE9NGHTqPZ-QnEHkEmB_l_NPt7wKnRuHb1WmExh55iK3LMKVLrdTdGQvEIpHmrjKOVSgAF3Z1M1qeDAI8DMuTsbSaCVbwRWxKLfznjXqv7Zv_gdB_cyn_Ck5nT8jjCVXmp6MZHJAHsX1KJOZw3CD5HvKuyQHp5RCHdY4js-MQ80ugoH1KYO_afL3Ffle48IxcnH399eW8mMYkFF6WelNoKYMVLtZSWMt9pJF5BaTXW-4s9Y5y552nzMbgqqamOvAG_NQ5oYO0ouHPyX7btfElyVUoaRmi4iIoLLF1lbbSeh88lU0sWUbYTkHGTz3EcZTFjUlcQkszKtWAUk1SquEZ-Tj_5nbsoHGv9GfU-yyJ3a_TF12_NpMzGQsoS3psxA9PlFlWB25l5RiwK1rbUGXkDT41M5aSzj5sTmV6Ma0rmZEPSQK9GP6At1MxAqgB-2EtJI8WkuB9frH8DizDXPurdKv4ue7MdW-AjnwzNdB8QIhwjZ3hmGmLGMydQWfk7byMl8e0tzZ2W5AB-Kg5MO46Iy9GO5s1w0uucMZQRtTCAheqW660V5epgbgC1M4lO7z_tl6RR2VyDszuPCL7m34bjwGBbdzr5GZ_AIrmKPI priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9RAEG52VxAv4tvoqlEEDxJNpzvdnYPIKi6rMJ4c2FvTr8wuOySamQH991Z1HhgZPHkKpCshqdTX_X2kq4qQl75StAbhkeWsUhlnocwqJ2VW1qwMzMiaB0xwXnwVZ0v-5bw8PyBju6PBgZu90g77SS279ZufP369B8C_i4BX4u2GA1QwzxhzpCmnGTsk12BlkgjUxUD3-6zhEiZfMebO7L10tj7FMv7TZH3YdPU-Ivr3fso_FqjTW-TmwCzTkz4UbpOD0Nwh1xfDv_O7ROCWjjVq8U3a1ikQvxSWZZViB-2wCekFKNIu7mdvm3S1w_JXOHCPLE8_fft4lg1dEzInCrXNlBDecBsqwY1hLuSBOgka2BlmTe5szqyzLqcmeFvWVa48qwG21nLlheE1u0-OmrYJD0kqfZEXPkjGvcSMW1sqI4xz3uWiDgVNCB19pd1QUhw7W6x1lBZK6N6_Gvyro381S8jr6ZrvfUGNf1p_wE8wWWIx7Hii7VZ6wJY2QLqEw7r8wAepoZVnRpSWgtjKK-PLhDzDD6j7zNIJ0vpExP_UqhQJeRUtMMzgBZwZchPADVgea2Z5PLMEMLrZ8AsIEn3lLuOj4nHV6qtOgzr5rCtQ_UAY4R5jDOkx4DUwKw7Ta87gnZ9Pw3h73AXXhHYHNsAmFQMBXiXkQR9yk2dYwSS2HEqInAXjzHXzkebyItYTl0DimaCP_oevH5MbRUQTbgk9JkfbbheeAG3b2qcRi78BCN855Q priority: 102 providerName: Scholars Portal |
| Title | Highlights of the 2018 Chinese hypertension guidelines |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32377372 https://www.proquest.com/docview/2404183033 https://www.proquest.com/docview/2399837179 https://pubmed.ncbi.nlm.nih.gov/PMC7193361 https://doaj.org/article/a3896c57821541a19d3a65b117409ad5 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002606173 |
| Volume | 26 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Clinical Hypertension, 2020, 26(3), , pp.20-25 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9RAEF9sBfFF_G60nlEEHyR0N7vZ3Tz2pKUKV6RYOHxZ9ittacnJffz_zmxy4SKiL74kcDsXkl9mdmbIzG8I-RBqzRpIPArKa10IHqui9koVVcOryK1qRMQG59m5PLsUX-fVfGfUF9aEdfTAHXBHFjyq9Ei6Ds6eWVYHbmXlGETStLYhsZeCz9tJprr-4Aq2WbntktHyaCXAnrAZGRupmWAFH3miRNg_bMt77bL5U8j5e-Xkjis6fUwe9TFkftzd-xNyL7ZPyYNZ_5X8GZFYvHGHWfcqXzQ5hHg5OGCd46zsuIr5NeSey1S5vmjzqw0SXeHCc3J5evL981nRz0covCz1utBSBitcrKWwlvtII_MKsl1vubPUO8qdd54yG4OrmprqwBsA0jmhg7Si4S_Ifrto4wHJVShpGaLiIijsrXWVttJ6HzyVTSxZRtgWK-N78nCcYXFnUhKhpenwNYCvSfganpFPw39-dtQZf5We4isYJJH2Ov0AymB6ZTD_UoaMvMUXaLoe0sF4zbFMX6R1JTPyMUmg-cIDeNt3IQAMSIQ1kjwcSYLZ-dHye1ASc-tv0q3i-WphbpcG8pAvpob8HkJDuMZWh0y_N6wMxFACNlLK4ZnfDct4eax3a-NiAzIQN2oOqXadkZedyg3I8JIrHC6UETVSxhF045X25joxhysI17lkr_4H1q_JwzJZExZ_HpL99XIT30CAtnYTsqfmakLuT0_Ov11MkmXCcSY0HC-mP34BXLY19Q |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELba7QEuCMQrUGhAIA4oahw7jnNAqIVWu7RdIdRKvRnHdrZVq6TsQ4g_xW9kxnmUINRbT5HiWSs7nteXzIOQNzaXtATgEcUslxFnLo1yk2VRWrLUMZ2V3GGB89FUjE_4l9P0dI387mphMK2ys4neUNva4DvybfA8HMQvZuzj1Y8Ip0bh19VuhEYjFgfu10-AbIsPk89wvm-TZH_v-NM4aqcKREYkchlJIazmhcsF15oZFztqMsCIRrNCx6aIWWEKE1PtbJGWeSwtK0Gsi4JLKzQvGey7TjY4AygzIhu7e9Ov367f6oD3437SK2VY9wIBSlepI8X2goNOY0E0FnNTTiM28IZ-aEDvGtarefm_sPff7M2_3OH-fXKvjWPDnUbwHpA1Vz0kArNGLhHuL8K6DCG2DMHzyxCHdLuFC88A9M59ynxdhbMVdtjChUfk5FZY-JiMqrpyT0mY2SROrMsYtxkW9Rap1EIbY00sSpfQgNCOQcq0XctxeMal8uhFCtUwVQFTlWeqYgF53__mqunZcSP1LvK9p8R-2_5GPZ-pVn2VhrhOGGz9DydKNc0t0yItKOC5ONc2DcgWnppqild7q6F2hP8ULlMRkHeeAu0G_AGj2_IHYAN24BpQbg4oQd_NYPk1SIa6MOf-UfE6q9XFXAEAmqg8hYA9S2CPTnBUa5QW6lqFAvKqX8btMdGucvUKaCBglQwwfh6QJ42c9ZxhCctwqlFAsoEEDlg3XKnOz3zL8gxwAhP02c2PtUXujI-PDtXhZHrwnNxNvKJgbukmGS3nK_cC4r9l8bJVupB8v209_wNvkmnR |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Highlights+of+the+2018+Chinese+hypertension+guidelines&rft.jtitle=Clinical+hypertension&rft.au=Jing+Liu&rft.date=2020-05-01&rft.pub=BMC&rft.eissn=2056-5909&rft.volume=26&rft.issue=1&rft.spage=1&rft.epage=6&rft_id=info:doi/10.1186%2Fs40885-020-00141-3&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_a3896c57821541a19d3a65b117409ad5 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2056-5909&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2056-5909&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2056-5909&client=summon |